Latest Innovation News

REA Group has reported a robust FY25 with strong revenue and profit growth, underpinned by solid Australian market performance and strategic moves in India. The company also announced a leadership transition amid optimistic FY26 guidance.

REA Group Ltd has reported robust FY25 results with a 15% increase in revenue and a 23% rise in core net profit, alongside a 31% lift in dividends. The company also announced the retirement of CEO Owen Wilson after a decade at the helm.

Vitrafy Life Sciences reported a 75% increase in FY25 sales driven by aquaculture and human health sectors, progressing its cryopreservation technology towards commercialisation in both unregulated and regulated markets in FY26.

Zoono Group Limited has closed its recent rights issue, raising $785,000 with a significant shortfall remaining. Managing Director Paul Hyslop fully subscribed and may provide further financial support as the company targets growth in Asia and product innovation.

Antilles Gold initiates a $650,000 share placement to fund working capital and prepare for a major $29.5 million EPC contract with Xinhai Mining, advancing the Nueva Sabana copper-gold mine development in Cuba.

EBR Systems has won final CMS approval for New Technology Add-On Payment reimbursement, paving the way for Medicare coverage of its innovative WiSE cardiac pacing system starting October 2025.

HeraMED Limited has resumed trading on the ASX following the release of its quarterly reports and a significant capital raising announcement, marking a pivotal moment for the medical device company.

Electro Optic Systems (EOS) has landed a landmark €71.4 million contract from a European NATO member for its pioneering 100kW high-power laser counter-drone system, marking the first export of this class of directed energy weapon.

Vitrafy Life Sciences reported strong FY25 progress with 75% sales growth, advanced cryopreservation technology development, and a robust cash position. The company outlines a clear commercialisation roadmap for FY26, including product launches and expanded U.S. operations.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

Telix Pharmaceuticals has recast its historical financials from AUD to USD to better reflect its US-centric revenue streams and reports increased operating expenditure tied to recent acquisitions and growth initiatives.

Credit Corp Group delivered a robust FY25 with a 16% increase in net profit after tax, driven by US debt buying and Australian/NZ lending growth. The company sets an ambitious FY26 outlook, underpinned by a record US investment pipeline and new product launches.